Atria Investments Inc Sells 647 Shares of BeiGene, Ltd. (NASDAQ:BGNE)

Atria Investments Inc cut its holdings in BeiGene, Ltd. (NASDAQ:BGNE) by 25.1% during the 3rd quarter, Holdings Channel reports. The firm owned 1,927 shares of the company’s stock after selling 647 shares during the period. Atria Investments Inc’s holdings in BeiGene were worth $433,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. XY Capital Ltd purchased a new stake in BeiGene in the third quarter worth about $6,839,000. Fiera Capital Corp lifted its holdings in shares of BeiGene by 60.9% during the third quarter. Fiera Capital Corp now owns 6,011 shares of the company’s stock valued at $1,350,000 after purchasing an additional 2,275 shares during the last quarter. Asset Management One Co. Ltd. lifted its holdings in shares of BeiGene by 14.5% during the third quarter. Asset Management One Co. Ltd. now owns 20,453 shares of the company’s stock valued at $4,592,000 after purchasing an additional 2,593 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its holdings in shares of BeiGene by 69.4% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,510 shares of the company’s stock valued at $1,911,000 after purchasing an additional 3,486 shares during the last quarter. Finally, PFG Investments LLC purchased a new position in shares of BeiGene during the third quarter valued at approximately $210,000. 48.55% of the stock is owned by institutional investors.

BeiGene Price Performance

NASDAQ BGNE opened at $194.26 on Thursday. The business’s fifty day moving average price is $212.60 and its 200-day moving average price is $182.77. The stock has a market capitalization of $18.92 billion, a price-to-earnings ratio of -23.58 and a beta of 0.63. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.93 and a quick ratio of 1.72. BeiGene, Ltd. has a 1-year low of $126.97 and a 1-year high of $248.16.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The company had revenue of $1 billion during the quarter, compared to analysts’ expectations of $983.26 million. BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company’s revenue for the quarter was up 28.2% on a year-over-year basis. During the same quarter last year, the company earned $2.01 earnings per share. On average, equities analysts predict that BeiGene, Ltd. will post -5.57 earnings per share for the current year.

Insiders Place Their Bets

In other BeiGene news, SVP Chan Henry Lee sold 1,202 shares of the stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $237.10, for a total transaction of $284,994.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John Oyler sold 6,175 shares of the stock in a transaction dated Tuesday, October 8th. The shares were sold at an average price of $232.22, for a total transaction of $1,433,958.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 23,070 shares of company stock worth $4,901,050. Corporate insiders own 7.43% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on BGNE. JMP Securities started coverage on shares of BeiGene in a report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 target price for the company. Citigroup upped their price objective on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research report on Thursday, August 8th. JPMorgan Chase & Co. upped their price objective on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a research report on Tuesday, October 22nd. StockNews.com cut BeiGene from a “buy” rating to a “hold” rating in a research report on Thursday. Finally, TD Cowen upped their price objective on BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $247.07.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.